Q-omics provides the consensus-scored NOS2 profile across patient tissues and cancer cell-line models. NOS2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NOS2 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, NOS2 RNA expression shows 15,738 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where NOS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOS2 survival associations across molecular data types. NOS2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOS2 RNA expression–survival associations across cancer types. High NOS2 expression shows unfavorable associations in MESO, BRCA and BLCA, but favorable associations in KIRC, HNSC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NOS2 RNA expression.
This table summarizes NOS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NOS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOS2 shows lower tumor expression in KICH, KIRP, UCEC and LUAD and higher tumor expression in LIHC and KIRC. The KICH box plot shows higher NOS2 RNA expression in normal versus tumor tissue (log2 FC = −1.223, t-test p < 0.001).
This table shows molecular features associated with NOS2 in patient tissues and cancer cell lines. In patient samples, NOS2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NOS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
